Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Stock Information for Interpace Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Interpace Biosciences Inc.

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.